The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An increase in oxidative stress and ROS production play a role in mitochondrial DNA damage, respiratory impairment, and calcium imbalance, where all these symptoms of mitochondrial dysfunction are associated with AD. 93”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neurodegeneration and cognitive deterioration can be influenced by the brain’s GLP-1 secretion and its peripheral in those affected by diabetes; however, external GLP-1 treatment may prove advantageous.92,93”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredIn the citing paper
“All GLP-1RAs have been found to cross the blood–brain barrier (BBB) and stimulate GLP-1 receptors in the brain, thus offering neuroprotection [17].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–231 of 231
Yang, Y., & Gao, L. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0922-0 · Cited by 36
Park, S. W., Mansur, R. B., Lee, Y. L., Lee, J.-H., Seo, M. K., Choi, A. J., McIntyre, R. S., & Lee, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00756 · Cited by 36
Ma, D., Liu, X., Liu, J., Li, M., Chen, L., Gao, M., Xu, W., & Yang, Y. (2019) · Brain Research · doi:10.1016/j.brainres.2019.02.030 · Cited by 33
Yang, Y., Ma, D., Xu, W., Chen, F., Du, T., Yue, W., Shao, S., & Yuan, G. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.10.005 · Cited by 32
The role of endoplasmic reticulum stress in hippocampal insulin resistance
Sims‐Robinson, C., Bakeman, A., Glasser, R., Boggs, J. M., Pacut, C. M., & Feldman, E. L. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.01.007 · Cited by 32
Wright, L. E., Vecellio Reane, D., Milan, G., Terrin, A., Di Bello, G., Belligoli, A., Sanna, M., Foletto, M., Favaretto, F., Raffaello, A., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00143.2016 · Cited by 32
Ferreiro, E., Lanzillo, M., Canhoto, D., Carvalho da Silva, A. M., Mota, S. I., Dias, I. S., Ferreira, I. L., Fontes, A. R., Mastrella, G., Pinheiro, P., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.003 · Cited by 32
Zhang, X., Tang, S. H., Zhang, Q.-H., Shao, W., Han, X., Wang, Y., & Du, Y. (2016) · Gene · doi:10.1016/j.gene.2016.05.018 · Cited by 31
Sedky, A. A., & Magdy, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119523 · Cited by 29
Wang, M., Yoon, G., Song, J., & Jo, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87809-4 · Cited by 28
Han, H., Wu, L., Ming-xiang, H., Yang, W., Wang, Y., & Fang, Z. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.05.011 · Cited by 27
Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?
Taga, M., Minett, T., Classey, J., Matthews, F. E., Brayne, C., Ince, P. G., Nicoll, J. A., Hugon, J., Boche, D., & CFAS, M. (2017) · Brain Pathology · doi:10.1111/bpa.12388 · Cited by 26
Wakabayashi, T., Hidaka, R., Fujimaki, S., Asashima, M., & Kuwabara, T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672857 · Cited by 26
Sacai, H., Sasaki‐Hamada, S., Sugiyama, A., Saitoh, A., Mori, K. J., Yamada, M., & Oka, J. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.02.002 · Cited by 25
Liao, T., Zhang, S., Yuan, X., Mo, W., Fang, W., Zhao, S., Yang, W., Liu, H., & Rong, X. (2019) · Obesity · doi:10.1002/oby.22666 · Cited by 25
Sasaki‐Hamada, S., Hojo, Y., Koyama, H., Otsuka, H., & Oka, J. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12891 · Cited by 23
Vaccari, C., Grotto, D., Pereira, T. D. V., de Camargo, J. L. V., & Lopes, L. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255726 · Cited by 23
Xiong, X., Lu, W., Qin, X., Luo, Q., & Zhou, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110218 · Cited by 22
Reisi, P., Alaei, H., Babri, S., Sharifi, M. R., Mohaddes, G., & Soleimannejad, E. (2009) · Pathophysiology · doi:10.1016/j.pathophys.2009.03.003 · Cited by 21
Changes in Synaptic Plasticity and Glutamate Receptors in Type 2 Diabetic KK-Ay Mice
Yin, H., Wang, W., Yu, W., Li, J., Feng, N., Wang, L., & Wang, X. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160858 · Cited by 21
Ciarmiello, A., Giovannini, E., Riondato, M., Giovacchini, G., Duce, V., Ferrando, O., Biasi, M. D., Passera, C., Carabelli, E., Mannironi, A., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04409-1 · Cited by 21
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus
Yao, Z., Liu, Y., Zhang, L., Huang, L., Ma, C., Xu, Y., Zhu, H., & Qin, C. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9859-6 · Cited by 20
Diabetes mellitus preserves synaptic plasticity in hippocampal slices from middle-aged rats
Tekkök, S. B., & Krnjević, K. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00662-9 · Cited by 19
Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide
Λαμπροπούλου, Ε., Lymperopoulou, A., & CHARONIS, A. S. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.011 · Cited by 16
Zhang, W., Hu, X.-F., Wan, N., Zhang, J., Yang, P. C., Wen, Q., Chen, W., Zhu, F., Liang, M., Cheng, L., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.160 · Cited by 16
Chen, D., Xiang, J.-N., & Yang, L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.072 · Cited by 14
Jing, G.-C., Zhang, M.-R., Ji, C., Zuo, P., Liu, Y.-Q., & Gu, B. (2016) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-016-2256-0 · Cited by 11
Insulin Treatment Prevents the Increase in D -Serine in Hippocampal CA1 Area of Diabetic Rats
Yang, J., Song, Y., Wang, H., Liu, C., Li, Z., Liu, Y., & Kong, Y. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514545379 · Cited by 8
Grimm, A., Schmitt, K., & Eckert, A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_9 · Cited by 8
Youssef, F. F., Manswell, S., & Homeward, L. (2009) · PubMed · Cited by 4
Barbero (2014) · doi:10.1016/j · Cited by 1
Research works printed but not linked: 3
- Youssef, 2009, West Indian Med J, 58, 410
- Qi, 2017, Am J Transl Res, 9, 247
- Egefjord, 2012, Dan Med J, 59, A4519
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“GLP-1 therapy decreased IL-1b mRNA production compared to the LPS alonetreated cultures (67, 72).”
BackgroundMetabolic memory: mechanisms and diseases
Dong, H., Sun, Y., Nie, L., Cui, A., Zhao, P., Leung, W. K., & Wang, Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01755-x · Cited by 213
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Monney, M., Jornayvaz, F. R., & Gariani, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101470 · Cited by 91
Metadata
- Authors
- Cheng, D., Yang, S., Zhao, X., & Wang, G.
- Affiliations
- First Hospital of Jilin University (CN)
- Corresponding author
- Wang, Guixia
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-03
- Volume
- Volume 16
- Pages
- 665-684
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC8943601
- OpenAlex
- W4221041575
- Cited by
- 84
- References
- 229
- Citations by year
- 2026: 21 · 2025: 27 · 2024: 13 · 2023: 18 · 2022: 5
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- People's Government of Jilin Province
- Jilin University
- First Hospital of Jilin University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- GLP-1 receptor agonists, neurodegenerative diseases, diabetes mellitus, Alzheimer's disease, Parkinson's disease, neuroprotection, type 2 diabetes, type 1 diabetes, obesity, cognitive impairment, molecular mechanisms
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Aged, Diabetes Mellitus, Type 2, Humans, Insulin, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.